Tessa Romero
Stock Analyst at JP Morgan
(4.14)
# 427
Out of 4,666 analysts
56
Total ratings
47.37%
Success rate
17.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UPB Upstream Bio | Initiates: Overweight | $38 | $18.01 | +110.99% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $9.79 | +53.22% | 4 | Nov 5, 2024 | |
| DYN Dyne Therapeutics | Downgrades: Neutral | $43 → $35 | $29.99 | +16.71% | 4 | Oct 24, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $0.81 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $27.86 | +11.27% | 5 | Oct 14, 2024 | |
| BHVN Biohaven | Maintains: Overweight | $55 → $68 | $46.83 | +45.21% | 5 | Oct 3, 2024 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $49.86 | +42.40% | 4 | Sep 5, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $8.96 | +223.84% | 3 | Aug 13, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $30 → $31 | $31.95 | -2.97% | 8 | Aug 12, 2024 | |
| AGIO Agios Pharmaceuticals | Reinstates: Neutral | $46 | $54.62 | -15.78% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $25 | $16.27 | +53.66% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $6.12 | +226.80% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $10.54 | -33.59% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $39.34 | +39.81% | 2 | Apr 25, 2023 |
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $18.01
Upside: +110.99%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $9.79
Upside: +53.22%
Dyne Therapeutics
Oct 24, 2024
Downgrades: Neutral
Price Target: $43 → $35
Current: $29.99
Upside: +16.71%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.81
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $27.86
Upside: +11.27%
Biohaven
Oct 3, 2024
Maintains: Overweight
Price Target: $55 → $68
Current: $46.83
Upside: +45.21%
Cytokinetics
Sep 5, 2024
Maintains: Overweight
Price Target: $65 → $71
Current: $49.86
Upside: +42.40%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $8.96
Upside: +223.84%
Edgewise Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $31.95
Upside: -2.97%
Agios Pharmaceuticals
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $54.62
Upside: -15.78%
Mar 25, 2024
Maintains: Overweight
Price Target: $29 → $25
Current: $16.27
Upside: +53.66%
Nov 28, 2023
Initiates: Overweight
Price Target: $20
Current: $6.12
Upside: +226.80%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $10.54
Upside: -33.59%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $39.34
Upside: +39.81%